Monoclonal antibodies (MAbs) were generated against lysates of clinical Mycoplasma hominis isolates. Three of these, designated BG2, BA10, and FE6, recognized an integral membrane protein of M. hominis with an apparent molecular weight of 50,000 (p50). Electron microscopy studies demonstrated that this protein is distributed evenly over the cell surface. These anti-p50 MAbs were species specific for M. hominis; they reacted with 42% of 126 tested clinical M. hominis isolates and showed no reactivity to heterologous mycoplasma species. Immunoblot analysis after limited proteolysis of purified p50 demonstrated that the three MAbs reacted with different epitopes of the protein. Unlike BA10 and FE6, MAb BG2 induced a decrease in arginine metabolism and a reduction of CFU in metabolic inhibition tests. F(ab)2 fragments of MAb BG2 showed the same inhibitory effect as the intact MAb molecule, while Fab and Fc fragments had no influence on vital functions. Preincubation of the mycoplasmas with MAb BG2 followed by trypsin treatment yielded the same amount of CFU as the control without antibodies. In conclusion, the cell aggregates were resolved by the trypsin treatment. These experiments and tests with the antibody fragments led to the conclusion that only the intact MAb structure or the F(ab)2 structure had metabolic inhibition potential and that the observed metabolism inhibition as well as the apparent decrease in viability were a result of agglutination by MAb BG2.
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In common with other Mollicutes, Mycoplasma hominis is an extracellular parasite which lacks a cell wall. A variety of disorders such as urinary tract infections and gynecological diseases are caused by this organism in humans (15) . In terms of pathogenicity, the mycoplasma membrane plays a prominent role in the interaction of the organism with the surface of host cells. Interaction as well as adhesion must be mediated in part by surface membrane structures (21) . In addition, the immunological response of the host to such mycoplasma surface structures may be an important factor in controlling or exacerbating the disease (e.g., see references 6 and 21) . In clinical diagnostics mycoplasmas are commonly identified to the species level by metabolism inhibition (MI) and growth inhibition, using polyclonal antisera (9, 13, 25) . Polyclonal antibodies directed against surface structures may be of major importance in causing inhibition of vital functions. However, a problem with these methods is that surface-localized epitopes exhibit strong variation (7) . Even though these methods are protracted and insensitive, MI and growth inhibition tests are widely used in diagnostic and epidemiological studies and in the classification and characterization of mycoplasmas (25) . The characterization of the surface structures responsible for the induction of antibody-mediated MI and growth inhibition is not possible with sera. Monoclonal antibodies (MAbs) have been used as specific tools in defining potentially important structures for MI and for the reduction of viability of M. hominis strains. Inhibition of growth or metabolism is described for different species of mycoplasmas and for antibodies directed against membrane proteins of different molecular weights (2, 11, 17, 28) . The basis of the MI reaction in mycoplasmas has not yet been elucidated (2 The immunoglobulin class of the generated MAbs was determined by ELISA, as described previously (3) .
Preparation of rabbit serum. Two-month-old New Zealand White rabbits were immunized subcutaneously with M. hominis FBG protein (1 mg/ml of PBS). Further booster injections were given at 10-to 14-day intervals. The sera were screened for anti-mycoplasma antibodies by ELISA. When sufficient antibodies had developed, the rabbits were bled and the sera were inactivated for 30 min at 56°C.
Preparation and purification of active Fab and F(ab)2 fragments. For preparation of Fab or F(ab)2 fragments, the MAbs were treated with papain or with preactivated papain, respectively, as described by Parham (19 (3) . The immunobinding assay was modified by the procedure of Kotani and McGarrity (10), as described previously (3) .
Cell lysis and isolation of membranes. Mycoplasma cell membranes were prepared by osmotic lysis as described by Razin (20) with the following modifications. A 100-ml broth culture of M. hominis grown to logarithmic phase was centrifuged at 12,000 x g for 15 min, washed twice in PBS, and resuspended in 2 ml of PBS. The cells were transferred rapidly into 100 volumes of deionized water, which was preheated to 37°C, and incubated for 15 min. The membranes were collected by centrifugation at 34,000 x g for 30 min, washed in deionized water, and finally resuspended in 5 ml of PBS-0.01 M 3-mercaptoethanol. The preparation was analyzed by the Bradford protein assay (5), SDS-PAGE, and immunoblotting.
Triton X-114 phase fractionation of mycoplasma components. The M. hominis proteins were separated by Triton X-114 phase fractionation as described by Bordier (4) eluted with 3 M NaSCN-0.1% Nonidet P-40 in PBS. The fractions which contained the p50 were pooled and dialyzed against PBS. Finally, the fraction was concentrated sevenfold by ultrafiltration, using a collodium bag, SM 13200 (Sartorius, Gottingen, Germany).
Immunoelectron microscopy. Mycoplasmas were prepared for electron microscopy as described by Christiansen et al. (7) with the following modifications. A 25-ml broth culture of mycoplasmas grown to the logarithmic phase was harvested by centrifugation (3,000 x g, 15 min) and washed twice in 25 mM Tris HCl (pH 7.0)-150 mM NaCl (TBS). For fixation, cells were resuspended in 1 ml of TBS-0.5% glutaraldehyde, centrifuged (3,000 x g, 15 min), and resuspended in 1 ml of TBS. The cell suspension (10 ,ul) was placed on top of a Formvar-carbon-coated, glow-discharged copper grid. Nonspecific binding sites were blocked with 0.5% bovine serum albumin (BSA); this was followed by incubation with MAb supernatants (BG2, BA10, FE6, and CCM2 [3] Ouchterlony immunodiffusion. Agarose, 1% in PBS buffer containing 0.05% sodium azide, was poured onto precoated slides, and agar plugs were withdrawn with a Pasteur pipette as described by Ouchterlony (18) . The wells were filled with 5 or 10 ,ul of antibody (1 mg/ml of PBS) and purified p50 (1 mg/ml). The slides were placed in a humid chamber and incubated overnight at 37°C. The precipitation rings were detected by Coomassie blue staining.
Inhibition of M. hominis metabolism by MAbs. The complement-independent metabolic inhibition potential of the anti-pSO antibodies was examined on the basis of two parameters: (i) the reduction of the metabolism of arginine via the arginine deiminase pathway, resulting in an alkaline shift in the pH of the medium; and (ii) reduction in M. hominis CFU. Each parameter will be considered in turn.
Inhibition of M. hominis metabolism of arginine by MAbs was analyzed by the MI tests of Washburn (27) Trypsin treatment of intact mycoplasmas. Mycoplasmas, grown for 24 h in the presence or absence of MAbs, were centrifuged and washed in PBS. The cell sediment was resuspended in 1 ml of 2.5% trypsin solution in PBS (Boehringer). The suspension was incubated at 4°C for 10 min. Mycoplasmas were sedimented by centrifugation at 13,000 x g for 10 min, the sediment was resuspended in broth culture medium and serially diluted, and CFU were quantified.
RESULTS
Specificity of MAbs. From a pool of MAbs generated after immunization of BALB/c mice with M. hominis FBG protein, three MAbs which reacted specifically with a protein with an apparent molecular weight of 50,000 were characterized [BG2, BA10, and FE6; all isotype IgGl(K)]. As shown in Fig. 1 E and F) . Lane G, Prestained molecular weight (MW) marker standards (a-macroglobulin, 180,000; ,3-galactosidase, 116,000; fructose-6-phosphate kinase, 84,000; pyruvate kinase, 58,000; fumarase, 48,500; lactic dehydrogenase, 36,500).
Cellular location of the p50 antigen. To determine the subcellular location of the p50 protein, membrane fractions of M. hominis FBG and PG21 were prepared by osmotic lysis and purified. As can be seen in Fig. 2 , the three MAbs bound to a protein found only in the membrane fraction and not in the cytoplasmic fraction.
Triton X(-114 partitioning of cell proteins was performed with M. hominis FBG and PG21 to assess the hydrophobicity of the MAb-reactive protein. Following partitioning, the proteins of the resulting fractions were immunoblotted and reacted with the MAbs. As shown in Fig. 2 , the p50 protein was found in the hydrophobic detergent phase following the extraction procedure, suggesting that p50 is an intrinsic membrane protein.
Immunoelectron microscopy of negatively stained mycoplasmas demonstrated that MAbs BG2, BA10, and FE6 react with surface-localized epitopes of the p50 protein. As shown in Fig. 3 Mapping of epitopes. The p5O protein was purified by affinity chromatography as described in Materials and Methods. The purified p50 protein was treated with V-8 protease (the enzyme hydrolyzes peptides at the carboxy-terminal side of glutamic acid), and the polypeptides thus produced were subjected to SDS-PAGE and immunoblot analysis. MAbs BG2, BA10, and FE6 were used for immunostaining of the protein blots, thereby identifying only those molecules which retain the epitope. In experiments with limited and complete V-8 protease digestion, p5O was degraded through intermediate products to fragments with molecular weights of <5,000. MAbs BA10, FE6, and BG2 recognized a polypeptide with a molecular weight of 12,000 as the smallest immunoreactive fragment. As shown in Fig. 4 Fig. 5 , MAb BG2, as well as the corresponding F(ab)2 fragment, inhibited the metabolism of M. hominis FBG. As a control, rabbit anti-M. hominis FBG serum wa -used. The polyclonal antibodies of the serum inhibited mycoplasma metabolism in the same way as MAb BG2. The control MAbs, directed against other membrane proteins of M. hominis of an apparent molecular weight of 60,000 (p60) or 100,000 (plOO) (CG4 = anti-p60 MAb; DC10 = anti-plOO MAb), did not affect the metabolic activity (Fig.  5) .
The apparent decrease in viability, manifested in the reduction of CFU, is correlated to the concentration of the added MAb BG2 (Fig. 6) . Analogous control experiments were performed with three other MAbs directed against membrane proteins p60 and plOO (MAbs CG4 and DC10) or against the intracellular EF-Tu (MAb CCM2) (3). These MAbs did not have any effect on the viability. Interestingly, MAb BA1O or FE6, which both react with the same p5O membrane protein but with different epitopes, had no or only a negligible effect (Fig. 7) .
To investigate these effects of MAb BG2 in more detail, the same experiments were performed with active Fab and F(ab)2 fragments. While the F(ab)2 fragments affected the metabolism and viability in the same way as the intact MAb, the Fab fragments did not show a comparable effect on vitality (Fig. 8) . Trypsin treatment of intact mycoplasmas after incubation with MAb BG2 or the antibody fragments led to the conclusion that only the intact MAb structure and the F(ab)2 structure had any influence on metabolism and growth ( Fig. 6 and 8 ). Photomicroscopic investigations of mycoplasmas grown in PPLO broth to the late logarithmic or the stationary phase showed that the mycoplasmas had agglutinated to clumps of very large numbers of cells (Fig.  9) . In control studies performed without any antibody, or with antibodies directed against other surface proteins, neither agglutination nor accumulation of cells was visible. In mycoplasma cultures incubated with rabbit anti-M. hominis FBG serum, the same amounts of aggregates were detectable. In the early logarithmic growth phase there was no agglutination visible. This indicated that the effect of MAb BG2 on the metabolism and viability of mycoplasmas is caused by an agglutination of cells mediated by MAb BG2.
DISCUSSION
Using hybridoma technology, our group has generated MAbs which bind to a variety or M. hominis epitopes. This multitude of MAbs has enabled us to analyze mechanisms of antibody-mediated inhibition of growth and metabolism. From these antibodies only MAb BG2, directed against the p50 protein, induced an apparent decrease in viability and an inhibition of metabolism (23) . Interestingly, two other MAbs, which also recognized the p50 protein, did not show these distinct effects on viability and metabolism. As shown by electron microscopy, the p50 protein is randomly distributed over the cell membrane and the recognized epitopes are localized on the surface. Cross-reactivity studies with other mycoplasma species and tests of antigen variability within M. hominis indicate that p50 is species specific for M. hominis. The epitopes recognized by MAbs BA10 and FE6 are frequently detected, whereas the epitope recognized by MAb BG2 is rarely detected on the different isolates. This indicates that the common epitopes to which BA10 and FE6 bind are more conservative.
To examine the cause of decreased metabolism and vitality mediated by the intact MAb BG2 molecule, analogous experiments were performed with the corresponding F(ab)2 and Fab fragments. The F(ab)2 fragments reacted in the same way as the intact BG2 molecule, whereas the Fab fragment had no influence on vital functions. These results show that the inhibition of metabolism and the concomitant apparent decrease in viability as a result of incubation with MAb BG2 are caused by agglutination. The agglutination is very stable since thorough resuspension does not disaggregate the complexes. Like the intact BG2 molecule, the bivalent F(ab)2 fragments retain the ability to agglutinate the mycoplasma cells. The agglutination of large numbers of mycoplasmas was visible in cultures grown to the late logarithmic phase when the concentration of cells was suitable to allow the buildup of such aggregates.
Trypsin treatment of the mycoplasmas after incubation with MAb BG2 causes a reversion to the normal logarithmic growth of mycoplasma cultures. Trypsin treatment leads to a proteolysis of surface-localized protein structures, including the bound BG2 MAb. It is not surprising, therefore, that MAb BG2 after trypsin treatment or the monovalent Fab fragments are capable of binding to the epitope but are not able to cross-link mycoplasma cells and induce a decrease in vital functions. It is important to emphasize that MAb BG2 is of the isotype IgGl. The observed reversion to the normal logarithmic growth demonstrates that this agglutination of M. hominis FBG and MAb BG2 permits multiplication of the organisms. As described earlier by Lin and Kass (14) , similar phenomena could be observed in MI tests with polyclonal antisera. The described reaction must be distinguished from usual agglutination reactions and effects that are independent of multiplication (14) .
Obviously, the other anti-p5O MAbs, BA10 and FE6, have no inhibitory effects on viability and metabolism, unlike MAb BG2. This suggests that only the epitope which is bound by BG2 is located in a sterically suitable position on the cell surface. The ability of MAb BG2, classified as IgGl, to precipitate the p50 protein, as shown by the Ouchterlony double-diffusion assay, indicates that the corresponding epitope is present in more than one copy on the protein molecule. These results demonstrate that the agglutination of the mycoplasmas by MAb BG2 is based on an immunological reaction of high specificity. A binding of immunoglobulin to a surface protein in a nonantigenic manner, as described by Alexander et al. (1) , can therefore be excluded. The biological function of p50 is still unclear. The role of the p5O protein in addition to other surface antigens in the pathogenicity of M. hominis is under investigation.
The inhibitory effects on vital functions as a consequence of cell agglutination by MAbs described in this study indicate that other similar metabolic inhibition phenomena induced by antisera or MAbs might not only result from inhibition of DNA replication and cessation of growth (11) , blocking of a specific metabolic function, or loss of membrane fluidity (2) but also could be caused or intensified by agglutination. Several other effects of MAbs on mycoplasma cells, such as inhibition of growth, adherence, hemadsorption, or monoclonal antibody killing, have been described (11, 16, 17, 21, 22, 28) . The agglutination of cells by antibodies could participate in the intensity of these phenomena. Even the inhibition of growth and metabolism for the serological identification of species (9, 25 ; see also references 29 and 30) could in part be based on agglutination by polyclonal antibodies. In all of these reports, the role of agglutination in inducing or enhancing the observed effects is not thoroughly investigated. It 
